CFMG & Wellpath in California — a documentary investigation · Article 022 of 100 · Series 3 — Physician executives, ownership and succession

Raymond Herr: The Physician Executive Who Bridges CFMG and the Enterprise

Published

20 September 2026, 6:00 PM PT

Content last changed

20 September 2026, 6:00 PM PT

Public-evidence cutoff

20 September 2026, 6:00 PM PT

Sources checked

20 September 2026, 6:00 PM PT

Record through

20 September 2026, 6:00 PM PT

Editorial status

Public-source editorial review complete

Evidence note. This article relies on public records and distinguishes established fact, party position, allegation, judicial finding, inference and unresolved question. Nothing here is a finding that any identified corporation or individual violated California law unless a cited adjudicative source expressly says so.

Opening frame#

Raymond Herr: The Physician Executive Who Bridges CFMG and the Enterprise is a governance inquiry, not a title-matching exercise. Corporate office, medical leadership, stock ownership, enterprise employment, and practical decision authority are treated as distinct evidentiary categories. The record is strongest where those categories converge in executed documents and weakest where succession or ownership instruments remain unavailable.

The governing question is narrow: How did Herr's roles span CFMG governance, policy, contracts, finance, and enterprise medicine? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material.

I. The Question and the Public Record#

The relevant public record is best read cumulatively. No single branding statement, county agenda item, corporate filing, bankruptcy disclosure, or management agreement resolves the entire relationship. The evidentiary value comes from comparing documents created for different purposes and asking whether they converge on the same allocation of identity, authority, economics, and professional responsibility.

Raymond herr — the longest documented post-founder president#

The public record supports a strong chronology for Herr:

• April 2015 — identified in Shepherd evidence as CFMG Chief Medical Officer and President.

• March 2017 — signs CFMG collective-bargaining agreement as President.

• December 2017 — signs Stanislaus contract as President.

• 2018 — identified by Alameda County as CFMG Chief Medical Officer and President.

• September 2018 — CDPH lists him as President and Chief Medical Officer.

• 2018 — signs Fresno CFMG agreement as President.

• 2020 — appears on Placer agreement as CFMG President.

• September 8, 2021 — signs Monterey Amendment No. 2 as CFMG President.

This is a substantial run of formal corporate/contractual evidence.

It gives Herr an unusually important place in the governance history because his tenure spans:

• the mature H.I.G./CMGC period;

• the 2018 CCS–CMGC combination;

• the creation of the Wellpath brand;

• the 2019 MSA assignment to Wellpath LLC.

The key unanswered question is:

What happened to the CFMG shareholder, board, and Company Designee structure during the 2018–2019 Wellpath transition while Herr was president?

The public governance record actually contains strong defense evidence#

An objective CPOM record must recognize that the governance history contains evidence supporting the legality of the structure.

• CFMG consistently existed as a separate California professional corporation.

• Physician presidents signed major county agreements.

• Current directors are physicians.

• CFMG remained a nondebtor PC during Wellpath bankruptcy.

• Post-bankruptcy contracts continue to be signed in CFMG's name.

• Wellpath publicly says CFMG is physician-owned.

• Hallman publicly said there was no ownership overlap.

• County contracts invoke ordinary corporate-signature formalities.

• The current Secretary of State filing names physician directors rather than Wellpath's nonphysician executive board.

These facts weigh against a simplistic "shell company" narrative.

Corporate disclosures — affiliate/parent labels as source-tracing material#

Several federal cases include corporate-disclosure entries describing CFMG and Wellpath through “affiliate,” “other affiliate,” or more expansive relationship labels.

These are useful for establishing that a disclosed corporate relationship existed or was represented.

They are poor substitutes for:

• stock ledgers;

• shareholder agreements;

• capitalization tables;

• governance instruments;

• or the MSA.

A Rule 7.1 label should therefore be coded:

relationship representation — authenticate underlying corporate basis.

Exact disclosure language is reproduced here only with:

• case;

• ECF number;

• filing date;

• filing party;

• signatory;

• and surrounding form context.

II. Structural and Historical Context#

From CFMG to the Wellpath Era: A California Corporate Timeline#

The modern CFMG–Wellpath structure is easier to understand when three histories are kept separate: the history of the California professional corporation, the history of the management enterprise around it, and the history of government contracts that continued through those changes.

A common mistake is to tell the story as a straight corporate succession:

CFMG → CMGC → Wellpath

The public documents do not support treating that shorthand as a complete legal genealogy.

A better model is three parallel tracks.

Records that would resolve the question#

• Actual Rule 7.1 / interested-entity PDFs from Beckner , Sand , Avila , Strieter , and post-bankruptcy CFMG cases.

• Every Overfield exhibit concerning Chapman termination.

• Chapman’s continued deposition once filed.

• Any renewed Hole deposition.

• Complete Smith same-entity stipulation and financial discovery record.

• Complete D.M. discovery correspondence supporting the same-functions representation.

• Complete Andrew Ho bankruptcy/arbitration references; public filings only.

• Napa Agreement 190201B and every amendment.

• County-by-county executed agreements and RFP proposals.

• CFMG/Wellpath quality-review policies implicated by Kartchner .

• Bankruptcy insurance/indemnity schedules naming CFMG.

• The 2012 MSA exhibits and every later amendment.

• All stock-transfer restriction / succession instruments referenced by the 2019 assignment.

• CFMG bylaws and shareholder/officer history.

• Physician employment templates pre-2018 vs post-2018.

• Wellpath enterprise clinical-policy approval matrices for California.

The correct treatment of the overlap#

the record should not invent a precise succession date from Fithian to Herr.

Possible explanations include:

• Fithian retained a founder/former-president title in pleadings describing earlier events;

• Herr assumed formal presidency during the middle of the decade;

• litigation allegations were historically dated rather than contemporaneous;

• different records used policy or medical titles imprecisely.

Until the corporate minutes and Secretary of State history are obtained, the transition should be described as:

By at least April 2015, Raymond Herr was being identified in contemporaneous operational records as CFMG President and Chief Medical Officer; litigation concerning earlier conduct continued to identify founder Taylor Fithian as President.

That formulation preserves the source conflict rather than silently resolving it.

III. The Control and Governance Analysis#

National vertical management model — research hypothesis#

A recurring feature of the Wellpath model is national vertical management. Public corporate materials describe a large multi-state enterprise headquartered in Tennessee. Operational records and employment communications in the public record indicate that California functions were frequently administered through Wellpath executives, HR personnel, legal/risk personnel, and clinical leadership outside the local county facilities.

The relevant issue is not geography. A physician executive may lawfully supervise clinicians from another state, and an MSO may lawfully centralize administrative services. The relevant issue is authority .

the record should test the following hypothesis:

CFMG physicians may have held formal professional-corporation offices while substantial day-to-day operational authority flowed vertically through Wellpath's national or regional chain of command, with local jail physicians and healthcare staff reporting through Wellpath-managed operational structures.

This hypothesis must be tested county by county and function by function.

The evidence required includes:

• organizational charts by year;

• reporting lines for physicians, nursing, mental health, pharmacy, and dental services;

• job descriptions for HSA, DON, site medical director, regional medical director, state medical director, chief medical officer, and operations executives;

• authority matrices;

• policy approval metadata;

• EHR access-control records;

• compensation approval chains;

• disciplinary/termination workflows;

• county-facing escalation protocols;

• CFMG board minutes showing actual physician deliberation.

Documents with the highest evidentiary value#

the investigation should prioritize obtaining and authenticating:

• complete December 31, 2012 MSA;

• all amendments and restatements;

• 2019 assignment documents;

• stock-transfer restriction agreements;

• shareholder succession / replacement agreements;

• CFMG articles, bylaws, shareholder agreements, and board minutes;

• complete list of CFMG shareholders/directors/officers by year;

• “Company Designee” appointments;

• Wellpath/CFMG delegation-of-authority matrices;

• physician hiring and termination workflows;

• physician compensation approval matrices;

• HRIS and payroll audit trails;

• EHR ownership and administrator records;

• clinical policy approval metadata;

• county RFP responses describing management hierarchy;

• malpractice/GL coverage and indemnity instruments;

• outside-counsel retention/claims administration protocols;

• quality assurance and mortality-review governance documents;

• management-fee and intercompany accounting records;

• post-bankruptcy amendments or succession instruments.

Subpages#

• Corporate timeline: 1983–2026

• The 2012 Management Services Agreement

• H.I.G. Capital and the 2013 investment

• The 2018 CCS–CMGC transaction and creation of Wellpath

• The 2019 management assignment

• CFMG physician ownership and governance

• California county contracts

• Physician employment and HR control

• Physician compensation and payroll

• Medical records and EHR control

• Clinical policy and operational control

• Litigation defense and claims administration

• Pre-bankruptcy litigation positions

• Bankruptcy and the rediscovery of CFMG

• Post-bankruptcy California litigation

• Smith v. Santa Cruz County

• D.M. v. County of Merced

• Hernandez v. County of Monterey

• Overfield v. Wellpath / CFMG

• Fresno case study: Miles, Henderson, and J.S.

• California CPOM law and 2026 enforcement

• Evidence matrix

• Case index

• Primary-document library

• Open questions / records not yet public

Every page should include a visible Evidence Level badge and a What this does not prove section.

Employment policy — the Wellpath handbook as enterprise evidence#

The Wellpath Team Member Handbook reviewed in the research corpus defines its scope to include Wellpath Holdings, subsidiaries, and entities managed by Wellpath LLC, collectively identified as Wellpath or “the Company.”

It also reserves broad policy authority to Wellpath and uses Wellpath as the actor in the general at-will termination language.

This is evidence of enterprise policy architecture .

It is not yet proof that every provision legally governed every CFMG physician. Indeed, contemporaneous internal correspondence requested clarification whether the handbook applied to CFMG physicians and, if not, what alternative CFMG HR framework governed them.

The unanswered legal/factual question is:

Was CFMG physician employment actually governed by an independent CFMG policy system, or by a Wellpath enterprise system with professional-corporation exceptions?

That question should be answered from:

• signed handbook acknowledgments;

• offer/employment agreements;

• policy headers and entity definitions;

• CFMG-specific supplements;

• state supplements;

• HRIS assignment;

• disciplinary workflows;

• termination approvals.

THE OVERRIDE TEST#

The most probative evidence of genuine physician independence may be actual conflict outcomes .

For each protected area, the record should look for instances where Wellpath and CFMG did not initially agree.

Then ask:

• Who proposed the action?

• Who objected?

• Who had formal approval rights?

• Who had practical veto rights?

• Whose position ultimately prevailed?

• Was the result documented as a CFMG physician decision?

• Could Wellpath implement the opposite result anyway?

Examples of highly probative records:

• CFMG physician rejects Wellpath HR termination recommendation;

• CFMG medical director refuses operations-imposed patient quota;

• CFMG physician approves referral after Wellpath administrative denial;

• CFMG board changes compensation model proposed by MSO;

• CFMG shareholder refuses proposed policy;

• Wellpath cannot replace or discipline physician decision-maker.

A lawful structure should produce at least some observable evidence of independent exercise of authority, especially over many years and many counties.

Absence of such records would not by itself prove sham governance, but it would increase the importance of the contractual control mechanisms.

Domain five — clinical policy and national vertical medical leadership#

A national Wellpath physician executive is still a physician. The fact that a clinical leader sits in Tennessee rather than California does not itself create a CPOM problem.

The questions are California licensure, CFMG authority, entity capacity, delegation, and final approval.

In April 2025, Wellpath’s Chief Medical Officer stated in writing that Wellpath was the Management Services Organization contracted to provide the full range of administrative services to CFMG . The same communication said Wellpath had reviewed disputed matters with CFMG leadership and was communicating with the CFMG physician with CFMG leadership’s knowledge and approval.

That evidence supports both sides:

Integration: a national Wellpath chief medical executive functioned as a central interface in a CFMG physician matter.

Potential independence/agency: he expressly represented that Wellpath was acting with CFMG leadership’s knowledge and approval.

Neither statement establishes whether CFMG approval was independent, contemporaneous, and meaningful.

For every enterprise clinical policy, the record should identify:

• who authored it;

• entity employing author;

• California licensure;

• who approved it for CFMG;

• whether CFMG-specific approval exists;

• whether CFMG could reject or modify it;

• whether CFMG ever did so;

• whether treating physicians could depart when clinically necessary.

Current assessment: National Wellpath clinical-leadership involvement is strong; CFMG’s contractual ultimate authority is strong; approval matrices and override evidence are missing.

Strongest evidence justifying further control investigation#

Conversely, several facts justify deeper investigation:

• The MSO is CFMG’s exclusive management-services provider.

• A management representative can attend and participate in CFMG equityholder/governance meetings, though without vote.

• CFMG physician employment forms are prepared by management and cannot be amended without management approval.

• The MSA assigns extensive physician HR functions to management.

• The MSA says management will determine physician base and incentive compensation .

• Management participates in staffing deliberations and schedule review.

• Wellpath publicly says it provides CFMG utilization-management functions.

• Management administers EMR systems and supervises storage/maintenance of patient records.

• Management negotiates client agreements and professional-service agreements on CFMG’s behalf.

• Management acquires/holds title to substantial equipment and recommends medical equipment.

• CFMG designated a Wellpath HR executive as Rule 30(b)(6) PMK about a CFMG physician termination.

• That witness testified the physician was terminated by management working for Wellpath.

• The Wellpath enterprise handbook is broad enough on its face to include entities managed by Wellpath LLC, while its exact application to CFMG physicians remains unresolved.

• Contemporaneous California operating records show Wellpath HR, clinical leadership, insurance, claims, and enterprise systems interacting directly with CFMG physician matters.

• The 2019 assignment transferred the MSA together with related stock-transfer restriction agreements into the Wellpath structure.

These facts do not establish illegality. They establish why approval and override evidence is essential.

Why these documents matter now#

California Attorney General enforcement in 2026 has focused directly on structures in which an MSO or private-equity-backed enterprise can:

• replace a physician shareholder;

• control who succeeds the shareholder;

• make physician ownership dependent on continued use of the MSO;

• prevent the physician practice from replacing the MSO without risking ownership.

That is precisely why the CFMG stock-transfer documents can no longer be treated as incidental corporate paperwork.

The decisive questions are:

• Who could become a CFMG shareholder?

• Who nominated or approved successors?

• Could Wellpath veto a proposed physician shareholder?

• Could Wellpath require replacement of a physician shareholder?

• What happened upon death, disability, loss of licensure, resignation, retirement, termination, or bankruptcy?

• Was any stock held in escrow?

• Did any proxy, option, nominee arrangement, succession list, or power of attorney exist?

• Who fixed the share-purchase price?

• Who funded the purchase?

• Did Wellpath or an affiliate possess a security interest tied to the shares?

• Could a physician owner remain owner after terminating the MSA?

• Could the physician owner sell to another qualified physician without Wellpath approval?

Until these instruments are obtained, no confident conclusion should be made about ultimate ownership succession.

The company-designee mechanism can concentrate CFMG corporate authority#

Section 1.4 of the MSA provides that when CFMG approval, consent, direction, or action is required, the action of the person designated as CFMG's Chief Executive Officer under its bylaws—the Company Designee —constitutes action of CFMG unless otherwise specified.

The management company may assume that required internal CFMG consents and approvals have been obtained.

This can be a commercially efficient agency mechanism.

But it can also become an evidentiary bottleneck.

If extensive CFMG corporate authority passed through one physician officer, the critical questions become:

• who held the Company Designee role each year;

• whether that person was a shareholder;

• whether that person held roles on the Wellpath/MSO side;

• what independent information the designee reviewed;

• whether board/shareholder deliberation occurred;

• whether the designee ever rejected management recommendations.

A structure can be formally physician-controlled while still concentrating all practical PC approval in one physician officer.

That is not automatically unlawful.

It does mean the independence of that office is central.

The same governance record also justifies deeper control review#

Other facts justify investigation rather than a presumption of independence:

• The original MSA was signed by the same CEO on both sides.

• H.I.G. was included in the MSA notice architecture from inception.

• The manager may attend and participate in CFMG governance meetings.

• Company action can be concentrated through a single Company Designee.

• The 2019 assignment transferred stock-transfer restriction agreements into the Wellpath management structure.

• Bazzel came from the pre-merger CCS executive structure.

• Medrano simultaneously holds Wellpath regional medical and CFMG corporate roles.

• CFMG's principal office migrated from California to Wellpath's Tennessee corporate infrastructure.

• Current officers/directors use the same Tennessee administrative locus.

• Current shareholders remain undisclosed in the public evidence.

• The actual stock-succession rules remain missing.

Again, those facts do not establish illegality.

They identify the precise governance records needed to answer the question.

THE MARCH 2026 LOCAL GOVERNMENT–CALIFORNIA REORGANIZATION CREATES A SECOND GOVERNANCE STRESS TEST#

On March 13, 2026, Wellpath announced creation of a new operating division:

Local Government–California

and appointed Jessica Mazlum as Division President.

Wellpath expressly described CFMG as:

• a Wellpath affiliate;

• a professional corporation;

• owned by licensed physicians;

• affiliated with Wellpath’s management-services organization.

Primary source:

https://wellpathcare.com/2026/03/13/wellpath-announces-creation-of-a-new-operating-division-in-california-appoints-new-highly-experienced-leader/

Wellpath also said the California operation would leverage the company’s enterprise data infrastructure.

This creates a new post-bankruptcy governance question:

What CFMG corporate action authorized the role of the Local Government–California division in the operations supporting CFMG’s California contracts?

Possible answers include:

• no CFMG approval was needed because the division was merely an internal MSO reorganization;

• CFMG approved a delegation;

• the existing MSA already allowed the reorganization;

• or amendments/delegation matrices were executed.

The public announcement does not answer that.

Again, the issue is not whether a nonphysician can lead an MSO division. A nonphysician can.

The question is where her authority ends and CFMG physician authority begins.

The strongest current documentary reconstruction is that the CFMG management relationship did not require a new publicly filed post-bankruptcy assignment to move from the H.I.G.-era enterprise into reorganized Wellpath.

The more likely mechanism is simpler:

Wellpath LLC was already the manager under the January 1, 2019 assignment; it entered Chapter 11 as the contracting debtor; the CFMG MSA was still being described by Wellpath as operative during bankruptcy; the final Plan deemed all executory contracts assumed unless specifically rejected or otherwise excepted; no California Forensic Medical Group / CFMG MSA entry has been located in the reviewed rejection notices or final rejection schedule; the Confirmation Order made those assumptions effective without further court order; and the assumed contract re-vested in the applicable contracting Post-Restructuring Debtor.

That chain makes deemed assumption by Wellpath LLC on the May 9, 2025 Effective Date the best-supported explanation for continuity of the CFMG MSA.

This conclusion rests on five independent documentary points. First, the January 1, 2019 Assignment expressly made Wellpath LLC the “Manager” under the CFMG MSA. Second, as late as February 11, 2025, Wellpath’s own bankruptcy filing described CFMG as a professional corporation to which the Debtors provided managerial services pursuant to the January 2019 CFMG MSA . Third, Article V of the confirmed Plan provides that, on the Effective Date, all executory contracts are deemed assumed by the applicable Post-Restructuring Debtor unless they fall within stated exceptions. Fourth, the final Rejected Executory Contracts Schedule filed April 29, 2025 affirmatively rejects another professional-corporation relationship— Grand Prairie Healthcare PC —while no CFMG / California Forensic Medical Group entry has been located in the searchable final schedule. Fifth, a 2026 Sonoma County professional-services agreement again expressly identifies Wellpath LLC as the Management Services Organization providing administrative services to CFMG .

The conclusion requires one important qualification. The precise Docket 194 schedule row and proposed cure amount for the CFMG MSA have not yet been located in the searchable public corpus, and this investigation has not located any private post-emergence amendment or CFMG board ratification. Accordingly, the statement that the CFMG MSA was deemed assumed is a high-confidence documentary/legal inference , not a substitute for obtaining the exact contract register and cure schedule.

IV. Contrary Evidence, Limits, and Competing Explanations#

A disciplined analysis must begin its limiting case with the strongest contrary evidence: The central limitation is the missing shareholder/stock-transfer record. Physician corporate titles are genuine governance evidence but are not proof of ownership or independence under disagreement.

Current evidence favoring structural independence#

The strongest evidence favoring genuine structural independence includes:

• CFMG remained a separate nondebtor professional corporation during Wellpath bankruptcy.

• Wellpath's own board co-chair publicly stated there was no ownership overlap.

• County materials describe CFMG as a separate physician-owned entity.

• CFMG signs county contracts through physician corporate officers.

• The MSA expressly preserves professional judgment.

• CFMG possesses contractual rights to terminate for material manager breach.

• Management's governance representative is expressly nonvoting.

• CFMG is the covered entity under HIPAA while management is the business associate.

• CFMG appears to own/hold the professional contracts with California counties.

• The MSA contemplates CFMG board evaluation of management performance and bonus determinations.

These facts are meaningful and must remain in the final analysis.

Clinical policy — enterprise standardization is not automatically unlawful#

National healthcare organizations commonly maintain enterprise policies.

A Wellpath policy appearing in a California jail does not, by itself, prove that Wellpath practiced medicine. The relevant questions are:

• Who authored the policy?

• Was it administrative or clinical?

• Did CFMG physician leadership review it before California implementation?

• Could CFMG modify it?

• Could a site physician depart from it based on patient-specific judgment?

• Who adjudicated exceptions?

• Who could discipline a physician for deviation?

• Who controlled version history?

• What happened when CFMG and Wellpath disagreed?

The strongest evidence of lawful independence would be a record showing CFMG physicians refusing, modifying, or conditioning a Wellpath clinical policy before implementation in California.

The strongest evidence pointing in the opposite direction would be a record showing a Wellpath enterprise policy imposed on CFMG physicians over a contrary physician-governance decision.

Until such records are obtained, “Wellpath policy” should be treated as evidence of infrastructure and standardization—not as dispositive evidence of unlawful control.

V. Missing Documents and Falsification Tests#

The record remains incomplete in material respects. Key unresolved points include the actual shareholder ledger, stock-transfer agreement, succession minutes, and the explanation for contradictory parent/subsidiary/affiliate filings.

Physician executive succession#

2019–2021. Herr remains central. By September 2021 a Monterey instrument identifies Herr as CFMG President and Judd Bazzel as Treasurer.

By September 2022. Public County agreements show Bazzel as CFMG President and Richard Medrano as Vice President/Secretary. The exact board/shareholder action producing this transition remains missing. No stock transfer should be inferred from officer succession.

By 2025. Corporate records identify Bazzel, Medrano, and Scott Kennedy as CFMG directors/officers. Their shareholder status remains unproved.

The documents that now matter most#

Tier One:

• Every stock-transfer restriction agreement referenced in the 2019 assignment.

• Current CFMG stock ledger.

• Current shareholder agreement.

• Shareholder succession agreements.

• Options, proxies, nominee agreements, powers of attorney.

• CFMG bylaws.

• Company Designee appointments.

• Full Deficit Funding Loan Agreement and amendments.

• UCC-1 financing statements and continuations/terminations.

• Current security agreements.

• Bank signature cards.

• ACH and treasury authorities.

• Deposit-account control agreements.

• 2012 Credit Agreement and successor/refinancing agreements.

• Every MSA amendment since 2012.

• Post-bankruptcy ratification/assumption documents.

• 2025–2026 CFMG board/shareholder minutes.

• Monthly management-company bonus resolutions.

• Management-fee/FMV analyses.

• Current New WPCC Parent capitalization and governance agreements.

Tier Two:

• Intercompany ledgers.

• CFMG general ledger.

• Wellpath management-fee invoices.

• Deficit-funding advance history.

• Insurance/claims agreements.

• IT/data exit provisions.

• county change-of-MSO approval provisions.

• employment/personnel transition restrictions.

• Local Government–California delegation matrix.

• documents showing whether CFMG considered alternative managers during bankruptcy.

CFMG Shareholders, Directors, Officers, Company Designees, Stock Succession, Cross-Roles, and the Search for the Missing Stock-Transfer Agreements#

the prior analysis establishes why ownership succession is the top unresolved structural issue.

the prior analysis should reconstruct:

• every identifiable CFMG shareholder;

• every president/CEO/secretary/CFO;

• every Company Designee;

• overlap with CMGC/Wellpath roles;

• corporate signature history;

• death/resignation/retirement succession events;

• public filings and county contracts;

• historical H.I.G./CMGC transaction representations;

• the most likely repositories for the missing stock agreements.

Only after that chain is reconstructed should the investigation draw any conclusion about who ultimately controlled CFMG ownership.

After six volumes, the most important remaining structural question is ownership.

This article produces a significant clarification:

The public record now permits a reasonably strong reconstruction of CFMG's corporate officers and directors over time, but it still does not identify the current CFMG shareholders or their percentages with sufficient reliability.

That distinction is critical.

A person can be:

• a physician;

• an officer;

• a director;

• a president;

• a chief executive officer;

• a Company Designee under the MSA;

• a medical director;

• a Wellpath executive;

• and even the person signing CFMG contracts

without necessarily being a shareholder.

Conversely, a shareholder may hold no public operating title.

Accordingly, officer succession cannot be treated as proof of stock succession .

The strongest current governance evidence is:

• the 2012 MSA;

• county contracts signed under California corporate formalities;

• California Secretary of State Statements of Information;

• federal litigation;

• labor agreements;

• the Wellpath bankruptcy;

• Wellpath public corporate materials.

Those records establish who held many formal offices.

They do not disclose the stock ledger.

The stock-transfer restriction agreements expressly referenced in the 2019 assignment therefore remain the single most important missing ownership source.

The stock-transfer restrictions could explain the succession pattern — but the documents are missing#

The 2019 assignment's express reference to "relevant stock transfer restriction agreements" becomes more important when placed beside the officer succession.

At least three major physician-leadership transitions occurred:

• Fithian era → Herr era;

• Herr era → transitional O'Bryan/Bazzel period;

• Bazzel era → current three-director board.

The unresolved question is whether any of these officer transitions coincided with stock succession.

Questions:

• Did Fithian sell or transfer shares?

• Did Herr acquire shares?

• Did Bazzel acquire shares?

• Were Medrano or Kennedy issued shares?

• Was a single physician shareholder replaced while board offices changed around that person?

• Did Wellpath or its predecessor have contractual approval over the transferee?

• Was stock held subject to a transfer restriction favoring the MSO?

• Did a physician's employment status affect ownership?

Those questions cannot be answered from public officer titles.

The stock documents are necessary.

The bankruptcy motion directly confirms stock-transfer agreements#

Before the bankruptcy review, the strongest evidence of CFMG stock-transfer restrictions came from the January 2019 assignment, which expressly transferred related instruments including “relevant stock transfer restriction agreements.”

Docket No. 15 materially strengthens that evidence at the enterprise level.

The Debtors disclosed that, in addition to PC Management Services Agreements, they and certain physician owners were parties to:

Stock Transfer Agreements

that:

• restrict transfer of a physician owner’s stock;

• facilitate a streamlined transition of ownership;

• promote compliance with state professional-entity requirements;

• address transfer events such as death and disability;

• promote continuity of care;

• and promote the continuation of administrative services by the Debtors .

The Debtors further stated:

Under the Stock Transfer Agreements, the Debtors have authority to ensure that the Professional Corporation is duly licensed and qualified.

This is one of the most important new findings in the entire record.

It establishes that stock-transfer arrangements were not merely passive restrictions designed to prevent transfer to an unlicensed person.

At least at the enterprise level, the Debtors themselves described the agreements as tools tied to:

• ownership transition;

• licensing continuity;

• and continuation of the Debtors’ management relationship.

That is precisely the type of contractual architecture California’s 2026 Art Center and Carbon Health enforcement developments make significant.

But a crucial limitation remains.

Docket No. 15 speaks generically about “certain PC Physicians.”

It does not publish the CFMG-specific Stock Transfer Agreement or state that every provision described applies identically to CFMG.

The CFMG connection is nevertheless stronger than a generic inference because the 2019 CFMG assignment independently confirms that relevant stock-transfer restriction agreements existed in the CFMG relationship .

The two sources therefore fit together:

2019 CFMG Assignment: CFMG-related stock-transfer restrictions existed and were assigned into the Wellpath structure.

2024 PC Motion: Wellpath explains the purposes and functions of Stock Transfer Agreements in its friendly-PC model generally.

The remaining question is the exact CFMG text.

The missing CFMG board record should not be treated as evidence of absence#

Because CFMG was a nondebtor, its ordinary board minutes would normally remain private corporate records.

A bankruptcy court generally does not require every nondebtor counterparty to publish internal deliberations merely because its contract partner files Chapter 11.

Therefore:

No public CFMG board minutes found ≠ no CFMG board deliberation occurred.

But where the substantive question is physician independence, those records become the best direct evidence.

The public record should therefore say:

No publicly filed CFMG board record has yet been identified showing how its physicians evaluated the manager’s bankruptcy and ownership transition.

That is accurate and neutral.

The bankruptcy record sharpens the central cpom question#

The bankruptcy evidence does not prove that Wellpath practiced medicine through CFMG.

It does something more useful.

It reveals the architecture of dependence .

The Debtors themselves described:

• a friendly-PC structure;

• physician ownership;

• deep administrative control;

• major economic reliance on PC revenues;

• stock-transfer restrictions tied to management continuity;

• authority relating to PC licensing/qualification;

• insurance;

• payroll;

• collections;

• taxes;

• legal support;

• indemnification;

• lender notice over new PC contracts.

California law then asks a separate question:

Did those structural rights and dependencies remain on the lawful administrative side of the line, or did they give the nonprofessional management enterprise practical or contractual authority over decisions reserved to physicians?

That question still requires the CFMG-specific stock, board, and authority records.

Tier-one open evidence#

The highest-value missing items remain:

• CFMG-specific stock-transfer restriction / succession agreement.

• CFMG stock ledger and shareholder roster by year.

• CFMG bylaws and Company-Designee appointments.

• Proxy, option, stock-power, escrow, nominee, or power-of-attorney instruments.

• Docket 194 CFMG assumption/cure row and proposed cure amount.

• CFMG board/shareholder minutes from the bankruptcy and emergence period.

• Deficit Funding Loan Agreement.

• UCC/security-interest records.

• Cash/bank signature and treasury authorities.

• Monthly CFMG management-bonus resolutions.

• Smith ECF 156 and full financial-discovery record.

• Full Overfield Chapman termination file/approval chain.

• Utilization-management denial/appeal/override records.

• Current Local Government–California delegation matrix.

• Post-emergence MSA/stock-instrument amendments or reaffirmations.

VI. Why the Issue Matters#

The stakes are practical rather than semantic. Counties need to know which entity is accountable for contracted performance; clinicians need to know where professional authority resides; courts and regulators need entity-specific evidence rather than brand shorthand; and the public needs a record that distinguishes corporate continuity from operational integration. Those distinctions become most important when the actors disagree, when a contract changes hands, when a professional decision conflicts with an economic preference, or when litigation requires a precise answer to who had authority to act.

VII. Falsification Tests and Evidentiary Limits Note#

The record does not support be read as establishing an unproven motive, an undisclosed shareholder, an unlawful medical override, or a legal conclusion that a court or regulator has not made. The strongest version of the thesis is the one that survives the missing-document test: identify the instrument, minutes, ledger, delegation, approval record, or disagreement event that would materially change the conclusion, then state what has and has not been found. If later primary evidence contradicts a proposition stated here, the correction should be made at the proposition level rather than defended through branding or organizational shorthand.

VIII. Related Articles#

• Article 021 — Taylor Fithian and the Founder-Era Governance Baseline

• Article 023 — Judd Bazzel: From Correct Care Clinical Executive to CFMG President

• Article 020 — Who Could Say No? The Demonstrated-Veto Test for Professional Independence

The proposition to be tested#

The central proposition in this article is not that every appearance of the Wellpath name proves control, nor that formal CFMG separateness ends the inquiry. The proposition to be tested is narrower: How did Herr's roles span CFMG governance, policy, contracts, finance, and enterprise medicine? A serious legal brief should state that proposition before discussing motive, liability, or remedy because the same document can be highly probative on one dimension and nearly irrelevant on another.

For this subject, the principal evidentiary dimensions are dual institutional roles, physician executive, contract authority, and enterprise integration. The source spine identified in the current public record is: CFMG contracts; NPPES; CBA; Johnson/Shasta exhibits; policy and mortality-review records. Those sources should not be pooled as though they were interchangeable. A county contract speaks most reliably to the county's counterparty and purchased obligations. A management agreement speaks to contractual allocation between the professional corporation and manager. A court order speaks to the matter actually adjudicated. A party filing or corporate announcement remains a representation unless independently adopted or found by a tribunal.

Governance evidence must distinguish office, employment, management title, board membership, shareholder status, delegated authority, and signature authority. These categories can overlap in one person without becoming legally interchangeable. The relevant capacity must be identified for each act. The practical advantage of that method is that it prevents a common failure in complex-enterprise investigations: using a true fact about one relationship as proof of a different relationship. A shared brand may show integration; a W-2 may show payroll identity; a contract signature may show authority to bind a corporation; an officer title may show corporate office. None automatically proves stock ownership or final clinical authority.

The charging or enforcement threshold, if any regulator ever considered one, would therefore require an evidence chain rather than a collage: identify the protected or regulated function; identify the actor with formal authority; reconstruct the first operative decision; identify the person or entity that could approve, reject, modify, or reverse it; and verify who implemented the result. Until that chain is complete, the proper classification is evidence, inference, or unresolved question—not adjudicated fact.

Weighing the evidence#

The evidentiary hierarchy for Raymond Herr: The Physician Executive Who Bridges CFMG and the Enterprise should begin with contemporaneous primary instruments and end with retrospective shorthand. Executed contracts, amendments, assignments, board resolutions, authenticated corporate records, court orders, government payroll or labor records, and formal agency records ordinarily deserve more weight on the proposition they were created to establish than marketing language or later summaries. Even among primary materials, however, purpose matters. A contract can establish contractual rights without proving that those rights were exercised; a tax record can establish reporting without deciding every common-law employer factor; a bankruptcy schedule can establish debtor treatment without answering professional-governance questions for a nondebtor corporation.

The article's existing record illustrates why that hierarchy matters.ithin its evidentiary lane. Raymond Herr: The Physician Executive Who Bridges CFMG and the Enterprise is a governance inquiry, not a title-matching exercise. Corporate office, medical leadership, stock ownership, enterprise employment, and practical decision authority are treated as distinct evidentiary categories. The record is strongest where those categories converge in executed documents and weakest where succession or ownership instruments remain unavailable.

A prosecutor, defense lawyer, regulator, or investigative editor should ask five questions of every source: Who created it? What legal or business purpose did it serve? What date and entity does it concern? Is the statement a recital, operative term, allegation, stipulation, finding, or marketing representation? What independent record could confirm or contradict it? Applying those questions consistently is more valuable than multiplying citations that all derive from the same underlying assertion.

This also defines how contradictions should be handled. When two records use different labels, the first step is not to accuse one of being false. The first step is to determine whether the records were answering different questions. Only after normalizing entity, date, capacity, forum, and purpose should a remaining contradiction be treated as substantive. That discipline makes the article stronger for both sides because it identifies where the record genuinely conflicts and where the conflict is merely semantic.

Chronology as a control test#

Chronology is often more probative than organizational charts. The decisive question is not merely who possessed authority on paper, but when a decision became operative and what happened immediately before and after that moment. A later board vote, HR notice, county communication, or litigation position may confirm, ratify, or explain an earlier act without proving who made the initial decision. Conversely, an early recommendation may have no legal effect until the authorized professional or contracting entity adopts it.

For Raymond Herr: The Physician Executive Who Bridges CFMG and the Enterprise, the chronology should be reconstructed with document-level precision. Investigators should place each significant contract, amendment, email that has entered the public record, board action, personnel or agency event that is lawfully publishable, and court filing on a single timeline. Each entry should identify the actor, capacity, entity, action verb, and legal effect. Terms such as “recommended,” “approved,” “directed,” “implemented,” “ratified,” “reported,” and “terminated” are not synonyms. The wording can reveal whether a participant supplied information, exercised discretion, or merely carried out another actor's decision.

The current article supplies anchor points that should remain central. The governing question is narrow: How did Herr's roles span CFMG governance, policy, contracts, finance, and enterprise medicine? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material. What happened to the CFMG shareholder, board, and Company Designee structure during the 2018–2019 Wellpath transition while Herr was president?

A robust chronology is also the best protection against overstatement. If the alleged controlling act occurred before the supposedly controlling actor entered the process, that theory weakens. If a professional body acted only after implementation, a claim that it supplied the first operative decision requires qualification. If the public record shows independent deliberation before implementation, that evidence materially strengthens the formal-independence account. The analysis therefore must treat time as an evidentiary variable, not just background narrative.

Sources and authorities#

1. Public records and authorities identified in the article body and source spine of the published record.